scholarly journals Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy

Cancer ◽  
2017 ◽  
Vol 124 (3) ◽  
pp. 459-465 ◽  
Author(s):  
Alana R. Donaldson ◽  
Caitlin McCarthy ◽  
Shazia Goraya ◽  
Holly J. Pederson ◽  
Charles D. Sturgis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Needle Biopsy ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Atypical Hyperplasia ◽  
Lobular Carcinoma In Situ ◽  
Core Needle

Breast Cancer Risk and Follow-up Recommendations for Young Women Diagnosed with Atypical Hyperplasia and Lobular Carcinoma In Situ (LCIS)

2015 ◽  
Vol 22 (10) ◽  
pp. 3346-3349 ◽  
Author(s):  
Maureen P. McEvoy ◽  
Suzanne B. Coopey ◽  
Emanuele Mazzola ◽  
Julliette Buckley ◽  
Ahmet Belli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Young Women ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Atypical Hyperplasia ◽  
Lobular Carcinoma In Situ

scholarly journals Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk

2015 ◽  
Vol 33 (33) ◽  
pp. 3945-3952 ◽  
Author(s):  
Tari A. King ◽  
Melissa Pilewskie ◽  
Shirin Muhsen ◽  
Sujata Patil ◽  
Starr K. Mautner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Cancer Incidence ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Lobular Carcinoma ◽  
Breast Cancer Incidence ◽  
Lobular Carcinoma In Situ

Purpose The increased breast cancer risk conferred by a diagnosis of lobular carcinoma in situ (LCIS) is poorly understood. Here, we review our 29-year longitudinal experience with LCIS to evaluate factors associated with breast cancer risk. Patients and Methods Patients participating in surveillance after an LCIS diagnosis are observed in a prospectively maintained database. Comparisons were made among women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophylactic mastectomies between 1980 and 2009. Results One thousand sixty patients with LCIS without concurrent breast cancer were identified. Median age at LCIS diagnosis was 50 years (range, 27 to 83 years). Fifty-six patients (5%) underwent bilateral prophylactic mastectomy; 1,004 chose surveillance with (n = 173) or without (n = 831) chemoprevention. At a median follow-up of 81 months (range, 6 to 368 months), 150 patients developed 168 breast cancers (63% ipsilateral, 25% contralateral, 12% bilateral), with no dominant histology (ductal carcinoma in situ, 35%; infiltrating ductal carcinoma, 29%; infiltrating lobular carcinoma, 27%; other, 9%). Breast cancer incidence was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001). In multivariable analysis, chemoprevention was the only clinical factor associated with breast cancer risk (hazard ratio, 0.27; 95% CI, 0.15 to 0.50). In a subgroup nested case-control analysis, volume of disease, which was defined as the ratio of slides with LCIS to total number of slides reviewed, was also associated with breast cancer development (P = .008). Conclusion We observed a 2% annual incidence of breast cancer among women with LCIS. Common clinical factors used for risk prediction, including age and family history, were not associated with breast cancer risk. The lower breast cancer incidence in women opting for chemoprevention highlights the potential for risk reduction in this population.

scholarly journals Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ

2018 ◽  
Vol 119 (1) ◽  
pp. 36-39 ◽  
Author(s):  
Louisa Lisa Lo ◽  
Roger Laughlin Milne ◽  
Yuyan Liao ◽  
Jack Cuzick ◽  
Mary Beth Terry ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Carcinoma In Situ ◽  
Lobular Carcinoma ◽  
Lobular Carcinoma In Situ
Sign in / Sign up

Export Citation Format

Share Document